ANXA2
ATC code L01
ATC code L04
Abagovomab
Abatacept
Abemaciclib
Abetimus
Abituzumab
Acalabrutinib
Acute disseminated encephalomyelitis
Adagrasib
Adalimumab
Adecatumumab
Adipotide
Adrenoleukodystrophy
Afatinib
Afelimomab
Aflibercept
Alectinib
Alefacept
Alemtuzumab (data page)
Alexander disease
Alpelisib
Amatuximab
American Society of Health-System Pharmacists
Amivantamab
Anakinra
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anatumomab mafenatox
Anifrolumab
Anti-lymphocyte globulin
Anti-thymocyte globulin
Antibody
Antibody-dependent cell-mediated cytotoxicity
Antifolate
Antigen
Antimetabolite
Antineoplastic
Apremilast
Asciminib
Ascrinvacumab
Aselizumab
Aspergillosis
Ataxia
Atezolizumab
Atezolizumab/hyaluronidase
Atorolimumab
Aumolertinib
Autoimmune disease
Avacopan
Avapritinib
Avelumab
Axatilimab
Axitinib
Azathioprine
BRAF (gene)
Balo concentric sclerosis
Balstilimab
Baricitinib
Basigin
Basiliximab
Bavituximab
Bayer AG
Bcr-abl fusion protein
Bectumomab
Begelomab
Belantamab mafodotin
Belatacept
Belimumab
Bermekimab
Bertilimumab
Bevacizumab
Bibcode (identifier)
Bimekizumab
Binimetinib
Biological half-life
Bivatuzumab mertansine
Blinatumomab
Blisibimod
Bosutinib
Botensilimab
Boxed warning
Brentuximab vedotin
Briakinumab
Brigatinib
Brodalumab
Brontictuzumab
Bruton's tyrosine kinase
C-Met
CAMFAK syndrome
CAS Registry Number
CD117
CD11a
CD135
CD154
CD18
CD20
CD23
CD30
CD33
CD3 (immunology)
CD4
CD40 (protein)
CD52
CD80
CDK inhibitor
CNS demyelinating autoimmune diseases
CTLA-4
Cabozantinib
Calcineurin
Canakinumab
Canavan disease
Cancer immunotherapy
Cantuzumab mertansine
Cantuzumab ravtansine
Capmatinib
Carotuximab
Catumaxomab
Cedelizumab
Cediranib
Cemiplimab
Central nervous system
Central pontine myelinolysis
Ceritinib
Certolizumab pegol
Cetuximab
ChEMBL
ChemSpider
Chemical formula
Chimeric antibody
Chloramphenicol acetyltransferase
Chronic inflammatory demyelinating polyneuropathy
Chronic lymphocytic leukemia
Ciclosporin
Cirmtuzumab
Citatuzumab bogatox
Cixutumumab
Cladribine
Clenoliximab
Clinical trial
Clinically isolated syndrome
Cobimetinib
Cofetuzumab pelidotin
Complement component 5
Complementarity-determining region
Conatumumab
Copanlisib
Cosibelimab
Crizotinib
Crovalimab
Cyclophilin
Cytomegalovirus
Dabrafenib
Dacetuzumab
Daclizumab
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Danicopan
Daratumumab
Darvadstrocel
Dasatinib
Dawson's fingers
Demcizumab
Denileukin diftitox
Denintuzumab mafodotin
Depatuxizumab mafodotin
Detumomab
Deucravacitinib
Deuruxolitinib
Diagnosis of multiple sclerosis
Diffuse myelinoclastic sclerosis
Dihydroorotate dehydrogenase
Dimethyl fumarate
Dinutuximab
Dinutuximab beta
Diplopia
Diroximel fumarate
Doi (identifier)
Dostarlimab
Drozitumab
DrugBank
Drug nomenclature
Drugs.com
Duligotumab
Durvalumab
Dusigitumab
Duvelisib
Duvortuxizumab
Dysarthria
Dysphagia
EML4
Ecromeximab
Eculizumab
Edrecolomab
Efalizumab
Efgartigimod alfa
Efgartigimod alfa/hyaluronidase
Elotuzumab
Elranatamab
Elsilimomab
Emactuzumab
Emapalumab
Emibetuzumab
Encorafenib
Enfortumab vedotin
Enoblituzumab
Enoticumab
Ensituximab
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlizumab
Erlotinib
Ertumaxomab
Etanercept
Etaracizumab
Etrasimod
European Medicines Agency
Everolimus
Exotoxin
Expanded Disability Status Scale
Experimental autoimmune encephalomyelitis
FDA
FKBP
Faralimomab
Farletuzumab
Fatigue
Fedratinib
Fibroblast growth factor receptor
Ficlatuzumab
Figitumumab
Filgotinib
Fingolimod
Flanvotumab
Flotetuzumab
Fludarabine
Fontolizumab
Food and Drug Administration
Frexalimab
Fruquintinib
Fusion protein
Futibatinib
Futuximab
Galiximab
Ganitumab
Gavilimomab
Gefitinib
Gemtuzumab ozogamicin
Genzyme
Gilteritinib
Girentuximab
Glasdegib
Glatiramer acetate
Glembatumumab vedotin
Glofitamab
Golimumab
Gomiliximab
Graft-versus-host disease
Greg Winter
Guselkumab
Gusperimus
HER2/neu
HIV-1
Hdl (identifier)
Hedgehog signaling pathway
Hematopoietic stem cell transplantation
Hereditary CNS demyelinating disease
Herman Waldmann
Humanized
Humanized antibody
IL-2 receptor
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
IgG1
Imatinib
Imgatuzumab
Immunoglobulin E
Immunomodulatory imide drug
Immunosuppression
Immunosuppressive drug
Inavolisib
Indatuximab ravtansine
Indium (111In) altumomab pentetate
Indium (111In) capromab pendetide
Indium (111In) igovomab
Indium (111In) satumomab pendetide
Inebilizumab
Infigratinib
Inflammatory demyelinating diseases of the central nervous system
Infliximab
Injection into a vein
Inolimomab
Inotuzumab ozogamicin
Integrin
Interferon
Interferon beta-1a
Interferon beta-1b
Interleukin
Interleukin-6 receptor
Interleukin 12
Interleukin 13
Interleukin 17
Interleukin 1 receptor antagonist
Interleukin 2
Interleukin 23
Interleukin 5
Interleukin 6
International nonproprietary name
Intetumumab
Intravenous infusion
Iodine (131 I) derlotuximab biotin
Ipilimumab
Iptacopan
Iratumumab
Isatuximab
Istiratumab
Itacitinib
Ixekizumab
Janus kinase
KEGG
KRAS
Keliximab
Krabbe disease
L-selectin
Labetuzumab
Lapatinib
Laquinimod
Larotrectinib
Lazertinib
Lebrikizumab
Leflunomide
Lenalidomide
Lenvatinib
Lerdelimumab
Lesional demyelinations of the central nervous system
Lestaurtinib
Leukemia
Leukoencephalopathy with vanishing white matter
Lexatumumab
Lifastuzumab vedotin
Lilotomab
Lintuzumab
List of multiple sclerosis organizations
List of people with multiple sclerosis
List of withdrawn drugs
Loncastuximab tesirine
Lorlatinib
Lorvotuzumab mertansine
Lucatumumab
Lumiliximab
Lumretuzumab
Lymphatic system
Lymphocyte
Lymphocyte function-associated antigen 1
Lymphoma
MEN1
MOG antibody disease
MTOR
MTOR inhibitor
Macrolide
Major depressive disorder
Management of multiple sclerosis
Mapatumumab
Marburg acute multiple sclerosis
Marchiafava–Bignami disease
Margetuximab
Masitinib
Maslimomab
Matuzumab
McDonald criteria
Medication
MedlinePlus
Megalencephalic leukoencephalopathy with subcortical cysts
Mepolizumab
Metachromatic leukodystrophy
Metelimumab
Methotrexate
Midostaurin
Milatuzumab
Minretumomab
Mirvetuximab soravtansine
Mitochondrial DNA depletion syndrome
Mitogen-activated protein kinase kinase
Mitoxantrone
Mitumomab
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Monomethyl fumarate
Morolimumab
Mosunetuzumab
Moxetumomab pasudotox
Multiple sclerosis
Multiple sclerosis drug pipeline
Muromonab-CD3
Mycophenolic acid
Myeloid
Nacolomab tafenatox
Naptumomab estafenatox
Narnatumab
Natalizumab
Naxitamab
Necitumumab
Neoplasm
Neratinib
Nerelimomab
Nesvacumab
Netakimab
Neuromyelitis optica spectrum disorder
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Nystagmus
Obinutuzumab
Ocaratuzumab
Ocrelizumab
Ocrelizumab/hyaluronidase
Odronextamab
Odulimomab
Ofatumumab
Off-label use
Olaratumab
Oligoclonal band
Olmutinib
Olokizumab
Omalizumab
Onartuzumab
Ontuxizumab
Opinercept
Oportuzumab monatox
Optic neuritis
Oregovomab
Orelabrutinib
Osimertinib
Otelixizumab
Otlertuzumab
Ozanimod
PDE4 inhibitor
PMC (identifier)
PMID (identifier)
Pacritinib
Pain
Palbociclib
Panitumumab
Parsaclisib
Parsatuzumab
Pascolizumab
Pathophysiology of multiple sclerosis
Patritumab
Pazopanib
Peficitinib
Pegcetacoplan
Pelizaeus–Merzbacher disease
Pembrolizumab
Pemigatinib
Pemtumomab
Pertuzumab
Pexelizumab
Pexidartinib
Pharmacokinetics
Phases of clinical research
Pi3K inhibitor
Pimecrolimus
Pinatuzumab vedotin
Pirfenidone
Pirtobrutinib
Platelet-derived growth factor receptor
Polatuzumab vedotin
Polyclonal antibodies
Pomalidomide
Ponatinib
Ponesimod
Poser criteria
Pralsetinib
Pregnancy category
Prescription drug
Pritumumab
Proapoptotic
Prohibitin
Prolgolimab
Purine synthesis inhibitor
Quizartinib
RET proto-oncogene
RTK class III
Racotumomab
Radiologically isolated syndrome